



US009408835B2

(12) **United States Patent**  
**Takae et al.**

(10) **Patent No.:** **US 9,408,835 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION**

(71) Applicant: **ASTELLAS PHARMA INC.**, Tokyo (JP)

(72) Inventors: **Seiji Takae**, Tokyo (JP); **Hiroyuki Kojima**, Tokyo (JP); **Atsushi Sakurai**, Tokyo (JP); **Tetsuya Tamura**, Tokyo (JP); **Hiroaki Tasaki**, Tokyo (JP); **Atsushi Muro**, Tokyo (JP)

(73) Assignee: **ASTELLAS PHARMA INC.**, Tokyo (JP)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/779,328**

(22) PCT Filed: **Mar. 28, 2014**

(86) PCT No.: **PCT/JP2014/059078**

§ 371 (c)(1),

(2) Date: **Sep. 22, 2015**

(87) PCT Pub. No.: **WO2014/157603**

PCT Pub. Date: **Oct. 2, 2014**

(65) **Prior Publication Data**

US 2016/0045479 A1 Feb. 18, 2016

(30) **Foreign Application Priority Data**

Mar. 29, 2013 (JP) ..... 2013-071361

(51) **Int. Cl.**

**A61K 31/437** (2006.01)

**A61K 9/20** (2006.01)

**A61K 9/28** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/437** (2013.01); **A61K 9/2054** (2013.01); **A61K 9/2095** (2013.01); **A61K 9/2806** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

#### U.S. PATENT DOCUMENTS

8,163,767 B2	4/2012	Inoue et al.	
8,779,140 B2 *	7/2014	Kikuchi	A61K 31/437 546/113
2005/0037067 A1 *	2/2005	Hovdal	A61K 9/2009 424/464
2013/0102628 A1	4/2013	Kikuchi et al.	
2014/0171464 A1	6/2014	Ishidoh et al.	

#### FOREIGN PATENT DOCUMENTS

JP	2004-131393 A	4/2004
WO	2007-0077949 A1	7/2007
WO	2011-142478 A1	11/2011
WO	2012-002547 A1	1/2012

#### OTHER PUBLICATIONS

Japanese Patent Office; Office Action in Japanese Patent Appl. No. 2015-508747, dated Nov. 2, 2015; English translation of Notice of Reasons for Rejection.  
International Search Report; PCT/JP2014/059078 dated Jun. 18, 2014.

\* cited by examiner

*Primary Examiner* — Robert A Wax

*Assistant Examiner* — Quanglong Truong

(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl] amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl] amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.

**10 Claims, No Drawings**